Cathepsin B: Multiple roles in cancer

Proteomics - Clinical Applications

Volumn 8, Issue 5-6, 2014, Pages 427-437

  Aggarwal, Neha ^a   Sloane, Bonnie F ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Cathepsin B; Cysteine proteases

Indexed keywords

CATHEPSIN B; CYSTEINE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; BREAST CARCINOMA; CANCER GROWTH; CELL INVASION; CELL MEMBRANE; CELL PROLIFERATION; CONTROLLED STUDY; METASTASIS; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN SECRETION; REVIEW; TRANSGENIC ORGANISM; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; NEOPLASM;

MURINAE;

ANIMALS; CATHEPSIN B; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS;

EID: 84901984899     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201300105     Document Type: Review

References (153)

1. Liu, Y. X., Liu, X. M., Nin, L. F., Shi, L. et al., Serine protease and ovarian paracrine factors in regulation of ovulation. Front. Biosci. 2013, 18, 650-664.
2. Barbolina, M. V., Stack, M. S., Membrane type 1-matrix metalloproteinase: substrate diversity in pericellular proteolysis. Semin. Cell Dev. Biol. 2008, 19, 24-33.
3. Szabo, R., Bugge, T. H., Membrane-anchored serine proteases in vertebrate cell and developmental biology. Annu. Rev. Cell Dev. Biol. 2011, 27, 213-235.
4. Georges, S., Ruiz Velasco, C., Trichet, V., Fortun, Y. et al., Proteases and bone remodelling. Cytokine Growth Factor Rev. 2009, 20, 29-41.
5. Staun-Ram, E., Miller, A., Cathepsins (S and B) and their inhibitor Cystatin C in immune cells: modulation by interferon-beta and role played in cell migration. J. Neuroimmunol. 2011, 232, 200-206.
6. Sabeh, F., Shimizu-Hirota, R., Weiss, S. J., Protease-dependent versus -independent cancer cell invasion programs: three-dimensional amoeboid movement revisited. J. Cell Biol. 2009, 185, 11-19.
7. Schaefer, A., Nethe, M., Hordijk, P. L., Ubiquitin links to cytoskeletal dynamics, cell adhesion and migration. Biochem. J. 2012, 442, 13-25.
8. Wolf, K., Friedl, P., Extracellular matrix determinants of proteolytic and non-proteolytic cell migration. Trends Cell Biol. 2011, 21, 736-744.
9. van Kempen, L. C., de Visser, K. E., Coussens, L. M., Inflammation, proteases and cancer. Eur. J. Cancer 2006, 42, 728-734.
10. Broder, C., Becker-Pauly, C., The metalloproteases meprin alpha and meprin beta: unique enzymes in inflammation, neurodegeneration, cancer and fibrosis. Biochem. J. 2013, 450, 253-264.
11. Heymann, M. C., Rosen-Wolff, A., Contribution of the inflammasomes to autoinflammatory diseases and recent mouse models as research tools. Clin. Immunol. 2013, 147, 175-184.
12. Reichel, C. A., Kanse, S. M., Krombach, F., At the interface of fibrinolysis and inflammation: the role of urokinase-type plasminogen activator in the leukocyte extravasation cascade. Trends Cardiovasc. Med. 2012, 22, 192-196.
13. Breuss, J. M., Uhrin, P., VEGF-initiated angiogenesis and the uPA/uPAR system. Cell Adhes. Migr. 2012, 6, 535-615.
14. Deryugina, E. I., Quigley, J. P., Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: contrasting, overlapping and compensatory functions. Biochim. Biophys. Acta 2010, 1803, 103-120.
15. Malla, R. R., Gopinath, S., Gondi, C. S., Alapati, K. et al., uPAR and cathepsin B downregulation induces apoptosis by targeting calcineurin A to BAD via Bcl-2 in glioma. J. Neuro-oncol. 2012, 107, 69-80.
16. Stoka, V., Turk, B., Turk, V., Lysosomal cysteine proteases: structural features and their role in apoptosis. IUBMB Life 2005, 57, 347-353.
17. Pop, C., Salvesen, G. S., Human caspases: activation, specificity, and regulation. J. Biol. Chem. 2009, 284, 21777-21781.
18. Ivanova, S., Repnik, U., Bojic, L., Petelin, A. et al., Lysosomes in apoptosis. Methods Enzymol. 2008, 442, 183-199.
19. Beck, I. T., The role of pancreatic enzymes in digestion. Am. J. Clin. Nutr. 1973, 26, 311-325.
20. Campbell, R. L., Davies, P. L., Structure-function relationships in calpains. Biochem. J. 2012, 447, 335-351.
21. Krane, S. M., Elucidation of the potential roles of matrix metalloproteinases in skeletal biology. Arthritis Res. Ther. 2003, 5, 2-4.
22. Troeberg, L., Nagase, H., Proteases involved in cartilage matrix degradation in osteoarthritis. Biochim. Biophys. Acta 2012, 1824, 133-145.
23. Baici, A., Lang, A., Zwicky, R., Muntener, K., Cathepsin B in osteoarthritis: uncontrolled proteolysis in the wrong place. Semin. Arthritis Rheum. 2005, 34, 24-28.
24. Yang, Y., Hill, J. W., Rosenberg, G. A., Multiple roles of metalloproteinases in neurological disorders. Prog. Mol. Biol. Transl. Sci. 2011, 99, 241-263.
25. Todi, S. V., Paulson, H. L., Balancing act: deubiquitinating enzymes in the nervous system. Trends Neurosci. 2011, 34, 370-382.
26. Luttun, A., Dewerchin, M., Collen, D., Carmeliet, P., The role of proteinases in angiogenesis, heart development, restenosis, atherosclerosis, myocardial ischemia, and stroke: insights from genetic studies. Curr. Atheroscler. Rep. 2000, 2, 407-416.
27. Lopez-Otin, C., Overall, C. M., Protease degradomics: a new challenge for proteomics. Nat. Rev. Mol. Cell Biol. 2002, 3, 509-519.
28. Rawlings, N. D., Barrett, A. J., Bateman, A., MEROPS: the database of proteolytic enzymes, their substrates and inhibitors. Nucleic Acids Res. 2012, 40, D343-D350.
29. Turk, V., Stoka, V., Vasiljeva, O., Renko, M. et al., Cysteine cathepsins: from structure, function and regulation to new frontiers. Biochim. Biophys. Acta 2012, 1824, 68-88.
30. Kirschke, H., Barrett, A. J., Rawlings, N. D., Proteinases 1: lysosomal cysteine proteinases. Protein Profile 1995, 2, 1581-1643.
31. Mort, J. S., Buttle, D. J., Cathepsin B. Int. J. Biochem. Cell Biol. 1997, 29, 715-720.
32. van der Stappen, J. W., Williams, A. C., Maciewicz, R. A., Paraskeva, C., Activation of cathepsin B, secreted by a colorectal cancer cell line requires low pH and is mediated by cathepsin D. Int. J. Cancer 1996, 67, 547-554.
33. Dalet-Fumeron, V., Guinec, N., Pagano, M., In vitro activation of pro-cathepsin B by three serine proteinases: leucocyte elastase, cathepsin G, and the urokinase-type plasminogen activator. FEBS Lett. 1993, 332, 251-254.
34. Dalet-Fumeron, V., Boudjennah, L., Pagano, M., Competition between plasminogen and procathepsin B as a probe to demonstrate the in vitro activation of procathepsin B by the tissue plasminogen activator. Arch. Biochem. Biophys. 1996, 335, 351-357.
35. Frosch, B. A., Berquin, I., Emmert-Buck, M. R., Moin, K. et al., Molecular regulation, membrane association and secretion of tumor cathepsin B. APMIS 1999, 107, 28-37.
36. Cavallo-Medved, D., Moin, K., Sloane, B., Cathepsin B. UCSD Nat. Mol. Pages 2011, doi:10.1038/mp.a000508.01.
37. Musil, D., Zucic, D., Turk, D., Engh, R. A. et al., The refined 2.15 A X-ray crystal structure of human liver cathepsin B: the structural basis for its specificity. EMBO J. 1991, 10, 2321-2330.
38. Keppler, D., Sloane, B. F., Cathepsin B: multiple enzyme forms from a single gene and their relation to cancer. Enzyme Protein 1996, 49, 94-105.
39. Illy, C., Quraishi, O., Wang, J., Purisima, E. et al., Role of the occluding loop in cathepsin B activity. J. Biol. Chem. 1997, 272, 1197-1202.
40. Quraishi, O., Nagler, D. K., Fox, T., Sivaraman, J. et al., The occluding loop in cathepsin B defines the pH dependence of inhibition by its propeptide. Biochemistry 1999, 38, 5017-5023.
41. Hughes, S. J., Glover, T. W., Zhu, X. X., Kuick, R. et al., A novel amplicon at 8p22-23 results in overexpression of cathepsin B in esophageal adenocarcinoma. Proc. Natl. Acad. Sci. USA 1998, 95, 12410-12415.
42. Ebert, M. P., Kruger, S., Fogeron, M. L., Lamer, S. et al., Overexpression of cathepsin B in gastric cancer identified by proteome analysis. Proteomics 2005, 5, 1693-1704.
43. Fernandez, P. L., Farre, X., Nadal, A., Fernandez, E. et al., Expression of cathepsins B and S in the progression of prostate carcinoma. Int. J. Cancer 2001, 95, 51-55.
44. Rempel, S. A., Rosenblum, M. L., Mikkelsen, T., Yan, P. S. et al., Cathepsin B expression and localization in glioma progression and invasion. Cancer Res. 1994, 54, 6027-6031.
45. Yan, S., Berquin, I. M., Troen, B. R., Sloane, B. F., Transcription of human cathepsin B is mediated by Sp1 and Ets family factors in glioma. DNA Cell Biol. 2000, 19, 79-91.
46. Kos, J., Werle, B., Lah, T., Brunner, N., Cysteine proteinases and their inhibitors in extracellular fluids: markers for diagnosis and prognosis in cancer. Int. J. Biol. Markers 2000, 15, 84-89.
47. Berquin, I. M., Cao, L., Fong, D., Sloane, B. F., Identification of two new exons and multiple transcription start points in the 5'-untranslated region of the human cathepsin-B-encoding gene. Gene 1995, 159, 143-149.
48. Li, L., Davie, J. R., The role of Sp1 and Sp3 in normal and cancer cell biology. Ann. Anat. 2010, 192, 275-283.
49. Dittmer, J., The biology of the Ets1 proto-oncogene. Mol. Cancer 2003, 2, 29-49.
50. Buggy, Y., Maguire, T. M., McGreal, G., McDermott, E. et al., Overexpression of the Ets-1 transcription factor in human breast cancer. Br. J. Cancer 2004, 91, 1308-1315.
51. Kars, M. D., Iseri, O. D., Gunduz, U., Drug resistant breast cancer cells overexpress ETS1 gene. Biomed. Pharmacother. 2010, 64, 458-462.
52. Dittmer, J., Vetter, M., Blumenthal, S. G., Lindemann, R. K. et al., Importance of ets1 proto-oncogene for breast cancer progression. Zentralbl. Gynakol. 2004, 126, 269-271.
53. Yan, S., Jane, D. T., Dufresne, M. J., Sloane, B. F., Transcription of cathepsin B in glioma cells: regulation by an E-box adjacent to the transcription initiation site. Biol. Chem. 2003, 384, 1421-1427.
54. Yan, S., Sloane, B. F., Isolation of a novel USF2 isoform: repressor of cathepsin B expression. Gene 2004, 337, 199-206.
55. Corre, S., Galibert, M. D., Upstream stimulating factors: highly versatile stress-responsive transcription factors. Pigment Cell Res. 2005, 18, 337-348.
56. Hu, J., Stiehl, D. P., Setzer, C., Wichmann, D. et al., Interaction of HIF and USF signaling pathways in human genes flanked by hypoxia-response elements and E-box palindromes. Mol. Cancer Res. 2011, 9, 1520-1536.
57. Semenza, G. L., Molecular mechanisms mediating metastasis of hypoxic breast cancer cells. Trends Mol. Med. 2012, 18, 534-543.
58. Baici, A., Muntener, K., Willimann, A., Zwicky, R., Regulation of human cathepsin B by alternative mRNA splicing: homeostasis, fatal errors and cell death. Biol. Chem. 2006, 387, 1017-1021.
59. Gong, Q., Chan, S. J., Bajkowski, A. S., Steiner, D. F. et al., Characterization of the cathepsin B gene and multiple mRNAs in human tissues: evidence for alternative splicing of cathepsin B pre-mRNA. DNA Cell Biol. 1993, 12, 299-309.
60. Berquin, I. M., Ahram, M., Sloane, B. F., Exon 2 of human cathepsin B derives from an Alu element. FEBS Lett. 1997, 419, 121-123.
61. Mighell, A. J., Markham, A. F., Robinson, P. A., Alu sequences. FEBS Lett. 1997, 417, 1-5.
62. Mehtani, S., Gong, Q., Panella, J., Subbiah, S. et al., In vivo expression of an alternatively spliced human tumor message that encodes a truncated form of cathepsin B. Subcellular distribution of the truncated enzyme in COS cells. J. Biol. Chem. 1998, 273, 13236-13244.
63. Muntener, K., Willimann, A., Zwicky, R., Svoboda, B. et al., Folding competence of N-terminally truncated forms of human procathepsin B. J. Biol. Chem. 2005, 280, 11973-11980.
64. Muntener, K., Zwicky, R., Csucs, G., Rohrer, J. et al., Exon skipping of cathepsin B: mitochondrial targeting of a lysosomal peptidase provokes cell death. J. Biol. Chem. 2004, 279, 41012-41017.
65. Sloane, B. F., Moin, K., Sameni, M., Tait, L. R. et al., Membrane association of cathepsin B can be induced by transfection of human breast epithelial cells with c-Ha-ras oncogene. J. Cell Sci. 1994, 107(Pt 2), 373-384.
66. Sameni, M., Elliott, E., Ziegler, G., Fortgens, P. H. et al., Cathepsin B and D are localized at the surface of human breast cancer cells. Pathol. Oncol. Res. 1995, 1, 43-53.
67. Rozhin, J., Robinson, D., Stevens, M. A., Lah, T. T. et al., Properties of a plasma membrane-associated cathepsin B-like cysteine proteinase in metastatic B16 melanoma variants. Cancer Res. 1987, 47, 6620-6628.
68. Demchik, L. L., Sameni, M., Nelson, K., Mikkelsen, T. et al., Cathepsin B and glioma invasion. Int. J. Dev. Neurosci. 1999, 17, 483-494.
69. Rozhin, J., Sameni, M., Ziegler, G., Sloane, B. F., Pericellular pH affects distribution and secretion of cathepsin B in malignant cells. Cancer Res. 1994, 54, 6517-6525.
70. Yan, Z., Deng, X., Chen, M., Xu, Y. et al., Oncogenic c-Ki-ras but not oncogenic c-Ha-ras up-regulates CEA expression and disrupts basolateral polarity in colon epithelial cells. J. Biol. Chem. 1997, 272, 27902-27907.
71. Vasiljeva, O., Papazoglou, A., Kruger, A., Brodoefel, H. et al., Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer. Cancer Res. 2006, 66, 5242-5250.
72. Cavallo-Medved, D., Dosescu, J., Linebaugh, B. E., Sameni, M. et al., Mutant K-ras regulates cathepsin B localization on the surface of human colorectal carcinoma cells. Neoplasia 2003, 5, 507-519.
73. Cavallo-Medved, D., Mai, J., Dosescu, J., Sameni, M. et al., Caveolin-1 mediates the expression and localization of cathepsin B, pro-urokinase plasminogen activator and their cell-surface receptors in human colorectal carcinoma cells. J. Cell Sci. 2005, 118, 1493-1503.
74. Victor, B. C., Anbalagan, A., Mohamed, M. M., Sloane, B. F. et al., Inhibition of cathepsin B activity attenuates extracellular matrix degradation and inflammatory breast cancer invasion. Breast Cancer Res. 2011, 13, R115-R128.
75. Recklies, A. D., Tiltman, K. J., Stoker, T. A., Poole, A. R., Secretion of proteinases from malignant and nonmalignant human breast tissue. Cancer Res. 1980, 40, 550-556.
76. Koblinski, J. E., Dosescu, J., Sameni, M., Moin, K. et al., Interaction of human breast fibroblasts with collagen I increases secretion of procathepsin B. J. Biol. Chem. 2002, 277, 32220-32227.
77. Linebaugh, B. E., Sameni, M., Day, N. A., Sloane, B. F. et al., Exocytosis of active cathepsin B enzyme activity at pH 7.0, inhibition and molecular mass. Eur. J. Biochem. FEBS 1999, 264, 100-109.
78. Klose, A., Wilbrand-Hennes, A., Zigrino, P., Weber, E. et al., Contact of high-invasive, but not low-invasive, melanoma cells to native collagen I induces the release of mature cathepsin B. Int. J. Cancer 2006, 118, 2735-2743.
79. Cavanaugh, P. G., Sloane, B. F., Bajkowski, A. S., Gasic, G. J. et al., Involvement of a cathepsin B-like cysteine proteinase in platelet aggregation induced by tumor cells and their shed membrane vesicles. Clin. Exp. Metastasis 1983, 1, 297-307.
80. Giusti, I., D'Ascenzo, S., Millimaggi, D., Taraboletti, G. et al., Cathepsin B mediates the pH-dependent proinvasive activity of tumor-shed microvesicles. Neoplasia 2008, 10, 481-488.
81. Mohamed, M. M., Sloane, B. F., Cysteine cathepsins: multifunctional enzymes in cancer. Nat. Rev. Cancer 2006, 6, 764-775.
82. Turk, V., Bode, W., The cystatins: protein inhibitors of cysteine proteinases. FEBS Lett. 1991, 285, 213-219.
83. Sloane, B. F., Cathepsin B and cystatins: evidence for a role in cancer progression. Semin. Cancer Biol. 1990, 1, 137-152.
84. Sloane, B. F., Moin, K., Krepela, E., Rozhin, J., Cathepsin B and its endogenous inhibitors: the role in tumor malignancy. Cancer Metastasis Rev. 1990, 9, 333-352.
85. Turk, B., Turk, V., Turk, D., Structural and functional aspects of papain-like cysteine proteinases and their protein inhibitors. Biol. Chem. 1997, 378, 141-150.
86. Abrahamson, M., Alvarez-Fernandez, M., Nathanson, C. M., Cystatins. Biochem. Soc. Symp. 2003, 70, 179-199.
87. Pavlova, A., Krupa, J. C., Mort, J. S., Abrahamson, M. et al., Cystatin inhibition of cathepsin B requires dislocation of the proteinase occluding loop. Demonstration by release of loop anchoring through mutation of his110. FEBS Lett. 2000, 487, 156-160.
88. Trinkaus, M., Vranic, A., Dolenc, V. V., Lah, T. T., Cathepsins B and L and their inhibitors stefin B and cystatin C as markers for malignant progression of benign meningiomas. Int. J. Biol. Markers 2005, 20, 50-59.
89. Sinha, A. A., Quast, B. J., Korkowski, J. C., Wilson, M. J. et al., The relationship of cathepsin B and stefin A mRNA localization identifies a potentially aggressive variant of human prostate cancer within a Gleason histologic score. Anticancer Res. 1999, 19, 2821-2829.
90. Sinha, A. A., Quast, B. J., Wilson, M. J., Fernandes, E. T. et al., Ratio of cathepsin B to stefin A identifies heterogeneity within Gleason histologic scores for human prostate cancer. Prostate 2001, 48, 274-284.
91. Shridhar, R., Zhang, J., Song, J., Booth, B. A. et al., Cystatin M suppresses the malignant phenotype of human MDA-MB-435S cells. Oncogene 2004, 23, 2206-2215.
92. Gondi, C. S., Rao, J. S., Cathepsin B as a cancer target. Expert Opin. Ther. Targets 2013, 17, 281-291.
93. Jedeszko, C., Sloane, B. F., Cysteine cathepsins in human cancer. Biol. Chem. 2004, 385, 1017-1027.
94. Kuester, D., Lippert, H., Roessner, A., Krueger, S., The cathepsin family and their role in colorectal cancer. Pathol. Res. Pract. 2008, 204, 491-500.
95. Mason, S. D., Joyce, J. A., Proteolytic networks in cancer. Trends Cell Biol. 2011, 21, 228-237.
96. Palermo, C., Joyce, J. A., Cysteine cathepsin proteases as pharmacological targets in cancer. Trends Pharmacol. Sci. 2008, 29, 22-28.
97. Sloane, B. F., List, K., Fingleton, B., Matrisian, L., Proteases in cancer-significance for invasion and metastasis, in: Brix, K. and Stoecker, W. (Eds.), Proteases-Structure and Function, Springer-Verlag, New York, in press.
98. Lakka, S. S., Gondi, C. S., Rao, J. S., Proteases and glioma angiogenesis. Brain Pathol. 2005, 15, 327-341.
99. Rao, J. S., Molecular mechanisms of glioma invasiveness: the role of proteases. Nat. Rev. Cancer 2003, 3, 489-501.
100. Koblinski, J. E., Ahram, M., Sloane, B. F., Unraveling the role of proteases in cancer. Clin. Chim. Acta 2000, 291, 113-135.
101. McKerrow, J. H., Bhargava, V., Hansell, E., Huling, S. et al., A functional proteomics screen of proteases in colorectal carcinoma. Mol. Med. 2000, 6, 450-460.
102. Srisomsap, C., Subhasitanont, P., Otto, A., Mueller, E. C. et al., Detection of cathepsin B up-regulation in neoplastic thyroid tissues by proteomic analysis. Proteomics 2002, 2, 706-712.
103. Wulfkuhle, J. D., Sgroi, D. C., Krutzsch, H., McLean, K. et al., Proteomics of human breast ductal carcinoma in situ. Cancer Res. 2002, 62, 6740-6749.
104. Krueger, S., Haeckel, C., Buehling, F., Roessner, A., Inhibitory effects of antisense cathepsin B cDNA transfection on invasion and motility in a human osteosarcoma cell line. Cancer Res. 1999, 59, 6010-6014.
105. Withana, N. P., Blum, G., Sameni, M., Slaney, C. et al., Cathepsin B inhibition limits bone metastasis in breast cancer. Cancer Res. 2012, 72, 1199-1209.
106. Tummalapalli, P., Spomar, D., Gondi, C. S., Olivero, W. C. et al., RNAi-mediated abrogation of cathepsin B and MMP-9 gene expression in a malignant meningioma cell line leads to decreased tumor growth, invasion and angiogenesis. Int. J. Oncol. 2007, 31, 1039-1050.
107. Gogineni, V. R., Gupta, R., Nalla, A. K., Velpula, K. K. et al., uPAR and cathepsin B shRNA impedes TGF-beta1-driven proliferation and invasion of meningioma cells in a XIAP-dependent pathway. Cell death Dis. 2012, 3, e439.
108. Rao Malla, R., Gopinath, S., Alapati, K., Gorantla, B. et al., Knockdown of cathepsin B and uPAR inhibits CD151 and alpha3beta1 integrin-mediated cell adhesion and invasion in glioma. Mol. Carcinog. 2013, 52, 777-790.
109. Girotti, M. R., Fernandez, M., Lopez, J. A., Camafeita, E. et al., SPARC promotes cathepsin B-mediated melanoma invasiveness through a collagen I/alpha2beta1 integrin axis. J. Invest. Dermatol. 2011, 131, 2438-2447.
110. Wang, Y. X., Lv, H., Li, Z. X., Li, C. et al., Effect of shRNA mediated down-regulation of Annexin A2 on biological behavior of human lung adencarcinoma cells A549. Pathol. Oncol. Res. 2012, 18, 183-190.
111. Sameni, M., Dosescu, J., Yamada, K. M., Sloane, B. F. et al., Functional live-cell imaging demonstrates that beta1-integrin promotes type IV collagen degradation by breast and prostate cancer cells. Mol. Imaging 2008, 7, 199-213.
112. Reisenauer, A., Eickelberg, O., Wille, A., Heimburg, A. et al., Increased carcinogenic potential of myeloid tumor cells induced by aberrant TGF-beta1-signaling and upregulation of cathepsin B. Biol. Chem. 2007, 388, 639-650.
113. Gupta, R., Nalla, A. K., Gogineni, V. R., Chetty, C. et al., uPAR/cathepsin B overexpression reverse angiogenesis by rescuing FAK phosphorylation in uPAR/cathepsin B down regulated meningioma. PloS One 2011, 6, e17123.
114. Bengsch, F., Buck, A., Gunther, S. C., Seiz, J. R. et al., Cell type-dependent pathogenic functions of overexpressed human cathepsin B in murine breast cancer progression. Oncogene 2013, doi:10.1038/onc.2013.395.
115. Sevenich, L., Werner, F., Gajda, M., Schurigt, U. et al., Transgenic expression of human cathepsin B promotes progression and metastasis of polyoma-middle-T-induced breast cancer in mice. Oncogene 2011, 30, 54-64.
116. Gocheva, V., Zeng, W., Ke, D., Klimstra, D. et al., Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev. 2006, 20, 543-556.
117. Ruffell, B., Affara, N. I., Cottone, L., Junankar, S. et al., Cathepsin C is a tissue-specific regulator of squamous carcinogenesis. Genes Dev. 2013, 27, 2086-2098.
118. Vasiljeva, O., Korovin, M., Gajda, M., Brodoefel, H. et al., Reduced tumour cell proliferation and delayed development of high-grade mammary carcinomas in cathepsin B-deficient mice. Oncogene 2008, 27, 4191-4199.
119. Cirman, T., Oresic, K., Mazovec, G. D., Turk, V. et al., Selective disruption of lysosomes in HeLa cells triggers apoptosis mediated by cleavage of Bid by multiple papain-like lysosomal cathepsins. J. Biol. Chem. 2004, 279, 3578-3587.
120. Droga-Mazovec, G., Bojic, L., Petelin, A., Ivanova, S. et al., Cysteine cathepsins trigger caspase-dependent cell death through cleavage of bid and antiapoptotic Bcl-2 homologues. J. Biol. Chem. 2008, 283, 19140-19150.
121. Foghsgaard, L., Wissing, D., Mauch, D., Lademann, U. et al., Cathepsin B acts as a dominant execution protease in tumor cell apoptosis induced by tumor necrosis factor. J. Cell Biol. 2001, 153, 999-1010.
122. Mathiasen, I. S., Hansen, C. M., Foghsgaard, L., Jaattela, M., Sensitization to TNF-induced apoptosis by 1, 25-dihydroxy vitamin D(3) involves up-regulation of the TNF receptor 1 and cathepsin B. Int. J. Cancer 2001, 93, 224-231.
123. Guicciardi, M. E., Bronk, S. F., Werneburg, N. W., Gores, G. J., cFLIPL prevents TRAIL-induced apoptosis of hepatocellular carcinoma cells by inhibiting the lysosomal pathway of apoptosis. Am. J. Physiol. Gastrointest. Liver Physiol. 2007, 292, G1337-G1346.
124. Spes, A., Sobotic, B., Turk, V., Turk, B., Cysteine cathepsins are not critical for TRAIL- and CD95-induced apoptosis in several human cancer cell lines. Biol. Chem. 2012, 393, 1417-1431.
125. Andl, C. D., McCowan, K. M., Allison, G. L., Rustgi, A. K., Cathepsin B is the driving force of esophageal cell invasion in a fibroblast-dependent manner. Neoplasia 2010, 12, 485-498.
126. Guo, M., Mathieu, P. A., Linebaugh, B., Sloane, B. F. et al., Phorbol ester activation of a proteolytic cascade capable of activating latent transforming growth factor-betaL a process initiated by the exocytosis of cathepsin B. J. Biol. Chem. 2002, 277, 14829-14837.
127. Gopinathan, A., Denicola, G. M., Frese, K. K., Cook, N. et al., Cathepsin B promotes the progression of pancreatic ductal adenocarcinoma in mice. Gut 2012, 61, 877-884.
128. Gounaris, E., Tung, C. H., Restaino, C., Maehr, R. et al., Live imaging of cysteine-cathepsin activity reveals dynamics of focal inflammation, angiogenesis, and polyp growth. PloS One 2008, 3, e2916.
129. Shchors, K., Nozawa, H., Xu, J., Rostker, F. et al., Increased invasiveness of MMP-9-deficient tumors in two mouse models of neuroendocrine tumorigenesis. Oncogene 2013, 32, 502-513.
130. Kato, Y., Ozawa, S., Miyamoto, C., Maehata, Y. et al., Acidic extracellular microenvironment and cancer. Cancer Cell Int. 2013, 13, 89-96.
131. Gatenby, R. A., Gillies, R. J., A microenvironmental model of carcinogenesis. Nat. Rev. Cancer 2008, 8, 56-61.
132. Wike-Hooley, J. L., Haveman, J., Reinhold, H. S., The relevance of tumour pH to the treatment of malignant disease. Radiother. Oncol. 1984, 2, 343-366.
133. Gillies, R. J., Raghunand, N., Karczmar, G. S., Bhujwalla, Z. M., MRI of the tumor microenvironment. J. Magn. Reson. Imaging 2002, 16, 430-450.
134. Glunde, K., Guggino, S. E., Solaiyappan, M., Pathak, A. P. et al., Extracellular acidification alters lysosomal trafficking in human breast cancer cells. Neoplasia 2003, 5, 533-545.
135. Estrella, V., Chen, T., Lloyd, M., Wojtkowiak, J. et al., Acidity generated by the tumor microenvironment drives local invasion. Cancer Res. 2013, 73, 1524-1535.
136. Rothberg, J. M., Sameni, M., Moin, K., Sloane, B. F., Live-cell imaging of tumor proteolysis: impact of cellular and non-cellular microenvironment. Biochim. Biophys. Acta 2012, 1824, 123-132.
137. Steffan, J. J., Snider, J. L., Skalli, O., Welbourne, T. et al., Na+/H +exchangers and RhoA regulate acidic extracellular pH-induced lysosome trafficking in prostate cancer cells. Traffic 2009, 10, 737-753.
138. Bell-McGuinn, K. M., Garfall, A. L., Bogyo, M., Hanahan, D. et al., Inhibition of cysteine cathepsin protease activity enhances chemotherapy regimens by decreasing tumor growth and invasiveness in a mouse model of multistage cancer. Cancer Res. 2007, 67, 7378-7385.
139. Elie, B. T., Gocheva, V., Shree, T., Dalrymple, S. A. et al., Identification and pre-clinical testing of a reversible cathepsin protease inhibitor reveals anti-tumor efficacy in a pancreatic cancer model. Biochimie 2010, 92, 1618-1624.
140. Schurigt, U., Sevenich, L., Vannier, C., Gajda, M. et al., Trial of the cysteine cathepsin inhibitor JPM-OEt on early and advanced mammary cancer stages in the MMTV-PyMT-transgenic mouse model. Biol. Chem. 2008, 389, 1067-1074.
141. Dennemarker, J., Lohmuller, T., Mayerle, J., Tacke, M. et al., Deficiency for the cysteine protease cathepsin L promotes tumor progression in mouse epidermis. Oncogene 2010, 29, 1611-1621.
142. Benavides, F., Perez, C., Blando, J., Contreras, O. et al., Protective role of cathepsin L in mouse skin carcinogenesis. Mol. Carcinog. 2011, 51, 352-361.
143. Wang, Q., Zhong, Y. J., Yuan, J. P., Shao, L. H. et al., Targeting therapy of hepatocellular carcinoma with doxorubicin prodrug PDOX increases anti-metastatic effect and reduces toxicity: a preclinical study. J. Transl. Med. 2013, 11, 192.
144. Nagler, D. K., Menard, R., Human cathepsin X: a novel cysteine protease of the papain family with a very short proregion and unique insertions. FEBS Lett. 1998, 434, 135-139.
145. Ritonja, A., Popovic, T., Kotnik, M., Machleidt, W. et al., Amino acid sequences of the human kidney cathepsins H and L. FEBS Lett. 1988, 228, 341-345.
146. Bromme, D., Li, Z., Barnes, M., Mehler, E., Human cathepsin V functional expression, tissue distribution, electrostatic surface potential, enzymatic characterization, and chromosomal localization. Biochemistry 1999, 38, 2377-2385.
147. Wiederanders, B., Bromme, D., Kirschke, H., von Figura, K. et al., Phylogenetic conservation of cysteine proteinases. Cloning and expression of a cDNA coding for human cathepsin S. J. Biol. Chem. 1992, 267, 13708-13713.
148. Yan, S., Sloane, B. F., Molecular regulation of human cathepsin B: implication in pathologies. Biol. Chem. 2003, 384, 845-854.
149. Deussing, J., von Olshausen, I., Peters, C., Murine and human cathepsin Z: cDNA-cloning, characterization of the genes and chromosomal localization. Biochim. Biophys. Acta 2000, 1491, 93-106.
150. Jean, D., Guillaume, N., Frade, R., Characterization of human cathepsin L promoter and identification of binding sites for NF-Y, Sp1 and Sp3 that are essential for its activity. Biochem. J. 2002, 361, 173-184.
151. Itoh, R., Kawamoto, S., Adachi, W., Kinoshita, S. et al., Genomic organization and chromosomal localization of the human cathepsin L2 gene. DNA Res. 1999, 6, 137-140.
152. Bakhshi, R., Goel, A., Seth, P., Chhikara, P. et al., Cloning and characterization of human cathepsin L promoter. Gene 2001, 275, 93-101.
153. Seth, P., Mahajan, V. S., Chauhan, S. S., Transcription of human cathepsin L mRNA species hCATL B from a novel alternative promoter in the first intron of its gene. Gene 2003, 321, 83-91.